Testing effectiveness (Phase 2)Active Not RecruitingNCT03236428
What this trial is testing
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Who this might be right for
Monoclonal GammopathySmoldering Multiple Myeloma
Dana-Farber Cancer Institute 42